Professor (tenured, endowed)University of Pennsylvania School Of Medicine

Printed as of 4/25/2024

Disclosures

Personal Commercial (8)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-----------------------|--|--------------------------|---------------------|
| Self | | | |
| Astra Zeneca | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |
| Bristol Meyers Squibb | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |
| Corvia | Other - I direct a research echo core lab.My staff performs blinded echo quantitation. I do not receive direct salary support. I am not part of steering committee meetings. I am not a co-author of publications. | None (\$0) | Noninvasive Imaging |
| Impulse Dynamics | Other - I direct a research echo core lab.My staff performs blinded echo quantitation. I do not receive direct salary support. I am not part of steering committee meetings. I am not a co-author of publications. | None (\$0) | Noninvasive Imaging |
| Medscape | Other - I gave a one-time interview/session about cardio- oncology (short podcast type discussion) | Modest (< \$5,000) | Other |
| Pfizer | Research/Research Grants | Significant (>= \$5,000) | Other |
| Roche | Consultant Fees/Honoraria | Modest (< \$5,000) | Other |
| Uptodate | Other - I authored a chapter for uptodate approximately 4 years ago and there is a very modest honorarium. | Modest (< \$5,000) | Other |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (5)

| Non-Commercial Enity Name | Relationship Category | Compensation Level | Topic Area(s) |
|--|---|--------------------------|------------------------------------|
| Self | | | |
| American College of Cardiology | Other - Editor-in-Chief, JACC: CardioOncology; in past 2 years, served as ACC Advancing the Cardiovascular Care of the Oncology Patient Co-Chair (modest) | Significant (>= \$5,000) | Other |
| American Heart Association | Research/Research Grants | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| National Institutes of Health | Research/Research Grants | Significant (>= \$5,000) | |
| Patient Centered Outcomes Research Institute | Research/Research Grants | Significant (>= \$5,000) | Other |
| Public Health Institute | Research/Research Grants | Significant (>= \$5,000) | Other |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 4/13/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement agreement

Embargo | Signed on 4/13/2024

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 4/13/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.